Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-09-07-Speech-3-294"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20050907.21.3-294"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
Mr President, Commissioner, ladies and gentlemen, as we have heard again today, there is still a lack of any gender-specific health policy in Europe. That is why the report by Mrs Svensson is so important, and I am much obliged to her for it. It is really no longer acceptable that most medicinal products are still tested only on men – another fact which has already been mentioned – even though we know that biological factors mean that medicinal products work differently on men and women.
It is also no longer acceptable that, for example, more women than men die of heart attacks, because the differing symptoms that occur in women mean that the condition is not diagnosed in time. It is equally incomprehensible, in my opinion, that there is still a complete absence of references to any gender-specific reactions in instruction leaflets for medicines. My group fully supports this report, therefore, as it requires Member States to finally take gender-specific health policy seriously.
Many of the demands put forward in this report are not new. This just goes to show how slowly the wheels of bureaucracy turn in the Member States. Although EU guidelines for the early detection of breast cancer in women aged between 50 and 69 have been in place since 1992, comprehensive mammography screening exists in only nine Member States. This can reduce mortality by 35%.
This report also calls for screening for women from the age of 40, subject to the availability of evidence-based data, as there are early indications that mortality can be reduced here, too, by up to 20%.
Another issue we regard as important is that of chlamydia infection. This disease leads to female infertility in one third of cases, where it has not been diagnosed in time. Further data on this are urgently needed.
By way of conclusion, I should like to draw attention briefly to a development that is going completely unnoticed by the public. Although Caesarean operations present an increased health risk to mother and child, the number of such operations is rising dramatically in several States. Causes seem to range from hospital doctors’ duty rosters, to supplementary income from private patients, to parents requesting particular appointment dates: holiday planning plays a major part in this.
Therefore, my group supports the call – addressed to Member States, in the first instance, of course – for attention to be drawn explicitly to the health risks of Caesareans to mother and child, which are five times greater than with natural births. However, we also support the call for the Commission to further study this phenomenon and gather and pass on the relevant data.
We also welcome the call for the Commission and the Member States to take every possible step to ensure that women finally receive a full explanation of the advantages and disadvantages of hormone replacement therapy."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples